APA

Ringdén O., Remberger M., Svenberg P., Svahn B., Dahllöf G., Gustafsson B., Hassan Z., Omazic B., Uzunel M., Aschan J., Barkholt L., Winiarski J., Ljungman P. & Mattsson J. (20070516). Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. : Bone marrow transplantation.

Chicago

Ringdén O, Remberger M, Svenberg P, Svahn B-M, Dahllöf G, Gustafsson B, Hassan Z, Omazic B, Uzunel M, Aschan J, Barkholt L, Winiarski J, Ljungman P and Mattsson J. 20070516. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. : Bone marrow transplantation.

Harvard

Ringdén O., Remberger M., Svenberg P., Svahn B., Dahllöf G., Gustafsson B., Hassan Z., Omazic B., Uzunel M., Aschan J., Barkholt L., Winiarski J., Ljungman P. and Mattsson J. (20070516). Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. : Bone marrow transplantation.

MLA

Ringdén O, Remberger M, Svenberg P, Svahn B-M, Dahllöf G, Gustafsson B, Hassan Z, Omazic B, Uzunel M, Aschan J, Barkholt L, Winiarski J, Ljungman P and Mattsson J. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. : Bone marrow transplantation. 20070516.